ERBB2 and breast carcinoma: In breast cancer patients, expression of PD-L2 correlates with overexpression of human epidermal growth factor receptor 2 (HER-2) and estrogen receptor (ER)-negative tumors, recurrence at distant sites, and younger patients’ age [19].